Differences

This shows you the differences between two versions of the page.

--- home:translations:norwegian [06.11.2018] – [Vitenskapelig grunnlag for behandlingen] sallieq
+++ home:translations:norwegian [05.10.2019] – [Data] sallieq
@@ Line 28: / Line 28: @@
 ===== Vitenskapelig grunnlag for behandlingen =====
-se også [[home:pathogenesis|Science behind Marshall Pathogenesis]],  [[home:protocol#science_behind_marshall_protocol|Science behind Marshall Protocol]], [[home:mp:stages|Stages of illness and recovery]]
+se også
+<relatedarticles>
+  * [[home:physicians:vitamin_d_leaflet|Testing your vitamin D metabolites]]
+  * [[home:pathogenesis|Science behind Marshall Pathogenesis]]
+  * [[home:protocol#science_behind_marshall_protocol|Science behind Marshall Protocol]]
+  * [[home:mp:stages|Stages of illness and recovery]]
+</article>
 Marshallprotokollen (MP) er navnet gitt til en behandling utarbeidet av professor Trevor Marshall. Den er basert på patogenesen han har foreslått for flere ulike kroniske sykdommer.
@@ Line 332: / Line 337: @@
 Pasienter som slutter med olmesartan utsetter helbredelsesprosessen.
+===== Data =====
+[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]
+[[home:food:aim_health:aging|Olmesartan research]]
+==== Response in 5 diagnoses ====
+ TOTALS: 864 members;573 report success; 119 report no success; and for 172 results are not clear.
+SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91%
+Sarcoidosis success 75.8%
+Chronic Fatigue Syndrome success 60.1%
+Lyme disease success 66.9%
+Rheumatoid arthritis success 69.2%
+Fibromyalgia success 64.2%
+All Other Th1 disease success 59.8%
 ==== Diverse av interesse for skandinaviske lesere ====

home/translations/norwegian.txt · Last modified: 09.14.2022 by 127.0.0.1